Market capitalization | DKK2.14t |
Enterprise Value | DKK2.22t |
P/E (TTM) P/E ratio | 20.77 |
EV/FCF (TTM) EV/FCF | 29.84 |
EV/Sales (TTM) EV/Sales | 7.32 |
P/S ratio (TTM) P/S ratio | 7.07 |
P/B ratio (TTM) P/B ratio | 15.65 |
Dividend yield | 2.33% |
Last dividend (FY24) | DKK11.40 |
As a Free StocksGuide user, you can view scores for all 6,872 stocks worldwide.
31 Analysts have issued a Novo Nordisk forecast:
31 Analysts have issued a Novo Nordisk forecast:
Mar '25 |
+/-
%
|
||
Revenue | 303,141 303,141 |
24%
24%
|
|
Gross Profit | 255,645 255,645 |
24%
24%
|
|
EBITDA | 155,307 155,307 |
29%
29%
|
EBIT (Operating Income) EBIT | 135,284 135,284 |
24%
24%
|
Net Profit | 104,615 104,615 |
17%
17%
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Head office | Denmark |
CEO | Lars Jørgensen |
Employees | 76,826 |
Founded | 1931 |
Website | www.novonordisk.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.